Keapstone Therapeutics
Pre-clinicalBy blocking this interaction, we can drive Nrf2 into the nucleus to activate a range of cellular defence pathways that improve redox balance and mitochondrial function, promote autophagy and limit inflammation. Uniquely, this approach allows multiple pathways to be targeted by a single drug.
Founded
2021
Focus
Small Molecules
About
By blocking this interaction, we can drive Nrf2 into the nucleus to activate a range of cellular defence pathways that improve redox balance and mitochondrial function, promote autophagy and limit inflammation. Uniquely, this approach allows multiple pathways to be targeted by a single drug.
Funding History
1Total raised: $3.2M
Seed$3.2MUK Innovation & Science Seed FundJan 15, 2022
Company Info
TypePrivate
Founded2021
LocationLondon, United Kingdom
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile